Cargando…

Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2–Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised Patients

We administered severe acute respiratory syndrome coronavirus-2 viral-specific T cells (VSTs) under emergency investigational new drug applications to 6 immunocompromised patients with persistent coronavirus disease 2019 (COVID-19) and characterized clinical and virologic responses. Three patients h...

Descripción completa

Detalles Bibliográficos
Autores principales: Haidar, Ghady, Jacobs, Jana L, Kramer, Kailey Hughes, Naqvi, Asma, Heaps, Amy, Parikh, Urvi, McCormick, Kevin D, Sobolewski, Michele D, Agha, Mounzer, Bogdanovich, Tatiana, Bushunow, Vasilii, Farah, Rafic, Hensley, Matthew, Hsu, Yen-Michael S, Johnson, Bruce, Klamar-Blain, Cynthia, Kozar, Jennifer, Lendermon, Elizabeth, Macatangay, Bernard J C, Marino, Christopher C, Raptis, Anastasios, Salese, Erin, Silveira, Fernanda P, Leen, Ann M, Marshall, William L, Miller, Michael, Patel, Badrish, Atillasoy, Ercem, Mellors, John W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495124/
https://www.ncbi.nlm.nih.gov/pubmed/37078720
http://dx.doi.org/10.1093/cid/ciad233
Descripción
Sumario:We administered severe acute respiratory syndrome coronavirus-2 viral-specific T cells (VSTs) under emergency investigational new drug applications to 6 immunocompromised patients with persistent coronavirus disease 2019 (COVID-19) and characterized clinical and virologic responses. Three patients had partial responses after failing other therapies but then died. Two patients completely recovered, but the role of VSTs in recovery was unclear due to concomitant use of other antivirals. One patient had not responded to 2 courses of remdesivir and experienced sustained recovery after VST administration. The use of VSTs in immunocompromised patients with persistent COVID-19 requires further study.